CoDa Therapeutics

CoDa CEO Bradford J. Duft

The biotech: CoDa Therapeutics
Round: $19.4 million
Based: San Diego
CEO: Bradford J. Duft
Investors: RusNano

The scoop: When Domain Associates announced earlier this year that it had struck up a close partnership with RusNano to help the Russian fund identify new investment opportunities, it may well have had CoDa in mind. Domain had already invested $20 million in CoDa's Series B, and the Russians would double down with another $20 million. CoDa's focus is on its Nexagon topical gel, which it boasts will help speed healing of diabetic foot ulcers and other wounds. The new deal with the Russians will call for some extra attention on that market, where RusNano is shepherding a fledgling biopharma industry. Also, it's the first of a number of new biotech investments expected from RusNano, which is finding plenty of places to place its bets.

For more:
Rusnano, Domain team top up CoDa venture round with $20M
CoDa banks $19M round for mid-stage wound healing study

CoDa Therapeutics
Read more on

Suggested Articles

exit
Biotech

Immuno-oncology vet Humphrey bids CytomX adieu

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

by Amirah Al Idrus
Back of man in long-sleeved shirt holding his neck and lower back. The places he's holding have red circles on them to indicate pain. An image of the spine is overlaid on his back.
Research

Scorpion toxin could inspire non-opioid pain treatments

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

by Arlene Weintraub
GSK CSO Hal Barron
Biotech

GSK's anti-BCMA drug hits goal in pivotal multiple myeloma test

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.

by Nick Paul Taylor